Merck KGaA drops divisional brands

14 October 2015

Germany’s Merck KGaA (MRK: DE) on Wednesday said it is eliminating its divisional brands Merck Serono and Merck Millipore, which will now uniformly operate under the name Merck outside of the USA and Canada, and has adopted a new company logo.

Karl-Ludwig Kley, chief executive, said: "Merck has fundamentally changed over the past ten years. The complete overhaul of our brand identity is to communicate this new direction vis-à-vis our customers, partners and applicants. We want to be recognizable and remain visible as Merck worldwide so as to strengthen our well-known brand name. For this we have deliberately rid ourselves of outdated features and will be focusing on a young and eye-catching image."

Going ahead, Merck Serono will operate as the biopharmaceutical business of Merck, and Merck Millipore as the life science business of Merck, it said in a statement. In the USA and Canada, pharma giant Merck & Co Inc (NYSE: MRK) holds the rights to the Merck name.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK